Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$86.50 USD
+0.69 (0.80%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $86.53 +0.03 (0.03%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EW 86.50 +0.69(0.80%)
Will EW be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EW based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EW
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth
EW: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?
HOLX or EW: Which Is the Better Value Stock Right Now?
Other News for EW
Med-tech and healthcare stocks with upside during 2Q earnings - Baird
September 20th Options Now Available For Edwards Lifesciences (EW)
Edwards Lifesciences: A Strategic Hold Amid Expansion and Anticipated Clinical Trials
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024
Edwards Lifesciences price target raised by $5 at Truist, here's why